BioCardia, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
BioCardia, Inc. (BCDA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $11.24 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $9.94.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.77, a 31.09% decline year-over-year.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $4.02, a 6.51% decline year-over-year.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2021-03-31 was $4.30, a 73.65% decline year-over-year.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $35.48, a 4.45% increase from fiscal 2024.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $33.97, a 6.42% decline from fiscal 2023.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $36.30, a 862.86% increase from fiscal 2022.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $3.77, a 16.04% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $11.24 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | $9.94 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | $35.48 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | $38.15 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $23.68 10-Q/A · filed 2025-10-29 | ||||
| 2024-12-31 | $33.97 10-K · filed 2026-03-24 | ||||
| 2023-12-31 | $36.30 10-K · filed 2025-03-26 | $2.42 10-K · filed 2024-03-27 | |||
| 2023-09-30 | $2.15 10-Q · filed 2023-11-08 | ||||
| 2023-06-30 | $2.36 10-Q · filed 2023-08-09 | ||||
| 2023-03-31 | $2.77 10-Q · filed 2023-05-10 | ||||
| 2022-12-31 | $3.77 10-K · filed 2023-03-29 | ||||
| 2022-09-30 | $3.77 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $3.68 10-Q · filed 2022-08-10 | ||||
| 2022-03-31 | $4.02 10-Q · filed 2022-05-11 | ||||
| 2021-12-31 | $4.49 10-K · filed 2022-03-29 | ||||
| 2021-09-30 | $4.71 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $4.57 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $4.30 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | $12.79 10-K · filed 2021-03-30 | ||||
| 2020-09-30 | $13.19 10-Q · filed 2020-11-10 | ||||
| 2020-06-30 | $19.73 10-Q · filed 2020-08-13 | ||||
| 2020-03-31 | $16.32 10-Q · filed 2020-05-15 | ||||
| 2019-12-31 | $26.86 10-K · filed 2020-04-09 | ||||
| 2019-09-30 | $14.16 10-Q · filed 2019-11-19 | ||||
| 2019-06-30 | $45.10 10-Q · filed 2019-08-14 | ||||
| 2018-12-31 | $2.92 10-K · filed 2019-04-02 | ||||
| 2018-09-30 | $2.93 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $2.69 10-Q · filed 2018-08-09 | ||||
| 2018-03-31 | $7.56 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $0.48 10-K · filed 2018-03-16 | ||||
| 2017-09-30 | $0.48 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $0.04 10-Q · filed 2017-08-14 | ||||
| 2017-03-31 | $0.04 10-Q · filed 2017-05-11 | ||||
| 2016-12-31 | $0.15 10-K · filed 2017-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |